ClinicalTrials.gg
Status unknownNCT05710367Updated Feb 2, 2023

Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

A Phase 2 interventional study of Dapagliflozin 10mg Tab and Placebo in Fabry Disease, sponsored by Albina Nowak, MD. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Albina Nowak, MD · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to test dapagliflizone in Fabry patients. The main questions it aims to answer are:

  • Has 10 mg/d of dapagliflozin a positive effect on kidney functions of Fabry patients.
  • Has 10 mg/d of dapagliflozin a positive effect on heart functions in Fabry patients.

Participants will be asked to

  • Sign an informed consent
  • Give a blood and urine samples
  • Be subjected to Echocardiography investigation
  • Take 10 mg/day Dapagliflizone

Researchers will compare treatment to placebo groups to see if kidneys and heart functions will be improved in the treatment group better more than the placebo group.

02

Conditions studied

  • Fabry Disease

Browse trials for

03

In context

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

This study's planned enrollment of 46 is above the median of 22 across 108 interventional studies indexed under Fabry Disease.

Browse Fabry Disease studies →

Lead sponsor

Albina Nowak, MD is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-70 years
  • Patients with genetically confirmed Fabry disease.
  • On treatment with Enzyme Replacement Therapy (ERT).
  • ERT or chaperone therapy at stable dose for at least 3 last months
  • Albuminuria >35 mg/day and/or proteinuria >150 mg/day
  • ≥25 mL/min/1.73 m2
  • On a stable dose of an ACEi, ARB or renin receptors blockers for at least 4 weeks prior to randomization
  • Sufficient command of German language.
  • Signed and dated .
  • Known cardiac association of FD

Exclusion criteria

Exclusion Criteria:

  • Known , allergy or to dapagliflozin.
  • Diagnosis of type 1 or type 2 diabetes mellitus
  • Patients with any disease (other than Fabry disease) affecting the heart and the kidnys.
  • History of kidney transplantation.
  • Active .
  • Use of the co-interventional treatments (Aldosterone antagonists, Continuous use of NSAIDs or systemic ) within 6 weeks of screening will not be allowed.
  • Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following:

    1. History of active inflammatory bowel disease within the last six months;
    2. Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;
    3. Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months;
    4. Pancreatic injury or pancreatitis within the last six months;
    5. Evidence of hepatic disease as determined by any one of the following: or AST values exceeding 3x at the screening visit, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt;
  • Subject who, in the assessment of the investigator, may be at risk for dehydration or volume depletion that may affect the interpretation of efficacy or safety data.
  • Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing.
  • Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.
  • Women who are pregnant or breast feeding; intention to become pregnant during the course of the study, lack of safe .
  • Patients with known or suspected non-compliance, drug or alcohol abuse, including Marijuana cigarettes.
  • Participation in another study with drugs within the 30 days preceding and during the present study.
  • Enrolment of the investigator, his/her family members, employees and other dependent persons.
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin 10mg Tab

    SGLT2is- Dapagliflozin (Forxiga): 10 mg/d, oral drug

    Drug: Dapagliflozin 10mg Tab

  • Placebo comparator
    Placebo

    Placebo tablet will have the same color, taste, smell and package as the verum tablet

    Drug: Placebo

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Forxiga® as an add-on treatment in patients with renal and/or cardiac association FD in an exploratory framework.

  • DrugPlacebo

    matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet

06

What researchers measure

Primary outcomes

  1. Assess the change of eGFR in treatment months 6, 12 and at baseline

    The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) 2009 formula are used to evaluate the calculated GFR. eGFR in month 6 and 12 are compared to baseline eGFR.

    Time frame: Baseline, 6 months and 12 months

  2. Assess the change of Protein /creatinine ratio in urine

    Total protein is measured in the morning sample of urine, minimal volume of 10 ml are collected and analyzed using Immune nephelometry method. Protein concentration are reported in relation to creatinine.

    Time frame: Baseline, 6 months and 12 months

  3. Assess the change of Albumin/creatinine ratio in urine

    Albumin is measured in the morning sample of urine, minimal volume of 10 ml are collected and analyzed using Immune nephelometry method. Albumin concentration are reported in relation to creatinine.

    Time frame: Baseline, 6 months and 12 months

Secondary outcomes

  1. NT-pro BNP level will be assessed at baseline and after 6 and 12 months of treatment with study drug and placebo

    NT-pro BNP are assessed using a minimal of 2.5 ml heparin-plasma sample with Electro- Chemiluminescent Immunoassay technique.

    Time frame: Baseline, 6 months and 12 months

  2. Troponin I levels will be assessed at baseline and after 6 and 12 months of treatment with

    Troponin I are measured in heparin whole blood (min. 2.5 ml) using Chemiluminescent Microparticle Immunoassay.

    Time frame: Baseline, 6 months and 12 months

  3. LVMMI parameter will be assessed at baseline and after 6 and 12 months of treatment with study drug and placebo

    LVMMI parameter are assessed using M-mode echocardiography in Cardiology clinic

    Time frame: Baseline, 6 months and 12 months

  4. Septal thickness parameter will be assessed at baseline and after 6 and 12 months of treatment with study drug and placebo

    Septal thickness parameter are assessed using M-mode echocardiography in Cardiology clinic

    Time frame: Baseline, 6 months and 12 months

Other outcomes

  1. Chlosterol level will be assessed at baseline and after 6 and 12 months of treatment with study drug and placebo

    Chlosterol level are measured using a minimal of 2.5 ml heparin-plasma sample with Enzymatic color test (CHOD-POD method)

    Time frame: Baseline, 6 months and 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Aug 2024, 12 months later.

Of 11 phase 2 interventional studies under Fabry Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 24. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Feb 2, 2023
StartEst.
Aug 2023
Primary completionEst.
Aug 2024
CompletionEst.
Aug 2024
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05710367
Lead sponsor
Albina Nowak, MD
Responsible party
Albina Nowak, MD (Principal Investigator, Senior Physician of Endocrinology, Diabetes and Clinical Nutrition, University of Zurich) — Sponsor-investigator
First posted
Feb 2, 2023
Start date
Aug 2023 (estimated)
Primary completion
Aug 2024 (estimated)
Completion
Aug 2024 (estimated)
Last update
Feb 2, 2023

Study contacts

Albina Nowak, MD
Contact
albina.nowak@usz.ch
+41 (0)43 253 8872
Israa Abdullah, MD-PhD
Contact
israa.abdullah@usz.ch
+41762710188

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion